Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US House 'Problem Solvers,' AdvaMed, Aim To Repeal Device Tax

Executive Summary

Two recent efforts to repeal the medical device tax include proposed legislation by a bipartisan "Problem Solvers" group of House members that includes a device-tax repeal provision, as well as an advertising campaign by AdvaMed.

You may also be interested in...



Medtech-Supporter Sen. Al Franken To Resign, After Harassment Charges

Sen. Al Franken, D-Minn., who has championed key device regulatory reform changes favoring the medtech industry that are now law, will step down from his post, following newly revealed charges of sexual harassment by a former congressional staffer in 2006.

AdvaMed 'Red Box' Targets Congress As Device-Tax Deadline Looms

The large medical device lobby group is keeping up its efforts to repeal the medical device excise tax, expanding its advertising buy on Capitol Hill with a new campaign as lawmaker return from recess.

Health Reform Roundtable Members Hold Conflicting Views On Device Tax Repeal For ACA Reform

A group of high-level health policy analysts – including former Medicare and Medicaid officials and experts at policy groups including Families USA and the American Enterprise Institute – have crafted a bipartisan recommendation for Affordable Care Act reform, but are divided on if the 2.3% device excise tax created by ACA should be repealed.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT105293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel